Anzeige
Mehr »
Donnerstag, 09.10.2025 - Börsentäglich über 12.000 News
Kursrakete 2025: CiTech präsentiert sich u.a. mit DroneShield neben Palantir & Rheinmetall - welche News sind zu erwarten?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P4YV | ISIN: US7291391057 | Ticker-Symbol: 9PT
Tradegate
08.10.25 | 19:52
1,310 Euro
-0,76 % -0,010
1-Jahres-Chart
PLIANT THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLIANT THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2901,33014:46
1,2901,33013:04

Aktuelle News zur PLIANT THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PLIANT THERAPEUTICS Aktie jetzt für 0€ handeln
08.08.Piper Sandler senkt Kursziel für Pliant Therapeutics drastisch auf 4,00 US-Dollar4
07.08.PLIANT THERAPEUTICS, INC. - 10-Q, Quarterly Report1
07.08.PLIANT THERAPEUTICS, INC. - 8-K, Current Report1
27.06.Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Update on BEACON-IPF6
09.06.PLIANT THERAPEUTICS, INC. - 8-K, Current Report4
21.05.Pliant Therapeutics präsentiert neue Daten zur Fibrose-Behandlung5
21.05.Pliant Therapeutics presents new fibrosis treatment data2
08.05.PLIANT THERAPEUTICS, INC. - 10-Q, Quarterly Report-
08.05.PLIANT THERAPEUTICS, INC. - 8-K, Current Report-
02.05.Pliant Therapeutics to trim about 45% of workforce2
02.05.Pliant Therapeutics cuts workforce by 45% after bexotegrast trial safety woes-
01.05.Pliant Therapeutics announces workforce reduction3
01.05.PLIANT THERAPEUTICS, INC. - 8-K, Current Report1
01.05.Pliant Therapeutics, Inc.: Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations188- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials - Pliant will reduce its current workforce by approximately 45% - Closing activities...
► Artikel lesen
13.03.Pliant Therapeutics, Inc.: Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement513SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder...
► Artikel lesen
03.03.Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis433SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial's...
► Artikel lesen
07.02.Pliant Therapeutics, Inc.: Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis530Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO...
► Artikel lesen
22.01.Pliant Therapeutics, Inc.: Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)139SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate...
► Artikel lesen
22.01.Pliant Therapeutics, Inc.: Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer1.724Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1